Credit Suisse’s Kazia Therapeutics KZIA Stock Holding History

Credit Suisse’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-107	Closed	-$92K	–	4588
2015 Q1	$92K	Buy	+107	New	+$61.4K	﹤0.01%	4232

Other funds holding KZIA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse's KZIA Position: Q2 2015 in Review

Credit Suisse sold out of Kazia Therapeutics (KZIA) in Q2 2015, closing a stake of 107 shares — an estimated $92K sold.

Credit Suisse first reported a position in KZIA in Q1 2015 and held it in 1 quarter. The position peaked at $92K in Q1 2015. 15 funds tracked by Wall St. Rank hold KZIA as of Q2 2015.

Credit Suisse reported no remaining Kazia Therapeutics position as of Q2 2015 after selling out during the quarter.
Credit Suisse sold 107 Kazia Therapeutics shares in Q2 2015, an estimated $92K.
Credit Suisse first reported a position in Kazia Therapeutics in Q1 2015 and held it in 1 quarter.
Credit Suisse's Kazia Therapeutics position peaked at $92K in Q1 2015.
15 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2015.

Based on Credit Suisse's 13F filing for Q2 2015, filed 13 Aug 2015.